Both simvastatin and rosuvastatin have similar side effects, including headache, nausea, vomiting, diarrhea, and muscle pain. Name must be less than 100 characters COVID-19 is an emerging, rapidly evolving situation. Free PMC article

2006 Mar;22(3):511-28. doi: 10.1185/030079906X89856.BMJ Open Diabetes Res Care. Actually, the decisions to switch from rosuvastatin to a potentially less effective intervention were taken by GPs, while the reasons for such a course of action in individual patients are not reported in the database. Both are effective "statins" to lower cholesterol. eCollection 2015. 2018 Oct 15;28(3):030703. doi: 10.11613/BM.2018.030713. 30 – 32 However, a meta-analysis of 14 clinical trials found that the reduction of … Please enable it to take advantage of the complete set of features! 2013;9:719-27. doi: 10.2147/VHRM.S49840.

2020 Jan;83:260-269. doi: 10.1016/j.bbi.2019.10.021. Managed Care & Healthcare Communications, LLC

COVID-19 is an emerging, rapidly evolving situation. Clipboard, Search History, and several other advanced features are temporarily unavailable. 2015 Apr 1;37(4):804-15. doi: 10.1016/j.clinthera.2014.12.019. 2013;9:719-27. doi: 10.2147/VHRM.S49840. More is spent in the US on rosuvastatin than any other statin. In a recent study of 641 703 patients in the UK prescribed different statins, those taking rosuvastatin had a significantly higher risk of an abnormally raised creatine phosphokinase activity than patients on large daily doses of other statins (simvastatin, pravastatin, or atorvastatin).16. Methods and Results-—Treatment effects on low- and high-density lipoprotein particle number (by NMR) and Lp-PLA 2 (by ELISA) were evaluated using plasma samples … Yet the evidence of its health benefits has always been weak and there is growing evidence of harmful side effects. Unable to load your delegates due to an error Differences between individual statins have been found in their potency to reduce low density lipoprotein cholesterol (LDL-C) and achieve lipid-lowering goals in both randomized trials 23 – 25 and observational studies. The second serious concern seen during preapproval trials was renal problems. Epub 2016 Sep 26. 2020 Jan 4;19(1):1. doi: 10.1186/s12944-019-1182-5.Fonkoue IT, Marvar PJ, Norrholm S, Li Y, Kankam ML, Jones TN, Vemulapalli M, Rothbaum B, Bremner JD, Le NA, Park J.Brain Behav Immun. 2015 Sep 23;3(1):e000132. Clinical Implications of Switching Lipid Lowering Treatment from Rosuvastatin to Other Agents in Primary Care. Epub 2013 Nov 15.McKenney JM, Jones PH, Adamczyk MA, Cain VA, Bryzinski BS, Blasetto JW; STELLAR Study Group.Curr Med Res Opin. [No authors listed] BACKGROUND: In Thai National List of Essential Drugs in 2010, simvastatin is the only medication on the list for the statin group.

Unable to load your collection due to an error Patients who previously prescribed other groups of statin were recommended to switch to simvastatin. A previous randomized, controlled study demonstrated greater LDL-C lowering in diabetic patients with symptomatic cardiovascular disease who switched from simvastatin 20 mg (S20) or atorvastatin 10 mg (A10) to combination ezetimibe/simvastatin 10/20 mg (ES10/20) therapy, compared with statin dose-doubling (to S40 or A20) or switching to rosuvastatin 10 mg (R10).

This site needs JavaScript to work properly. Epub 2013 May 30.Atheroscler Suppl. Epub 2013 Nov 15.Jimenez JG, Rosen JB, Pirags V, Massaad R, Hanson ME, Brudi P, Triscari J.Diabetes Obes Metab. 11 Of note, the switching rates for E/S therapy in the [Ngoc‐Anh Le and Peter W. F. Wilson] and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Using generic simvastatin as first line could save £2bn over five years in England S tatins are one of the great success stories of preventive medicine. This site needs JavaScript to work properly. 2006 Apr;26(4):469-78. doi: 10.1592/phco.26.4.469.Curr Med Res Opin. Epub 2019 Nov 1.Fonkoue IT, Le NA, Kankam ML, DaCosta D, Jones TN, Marvar PJ, Park J.Physiol Rep. 2019 Apr;7(7):e14057. All rights reserved. Name must be less than 100 characters Relationship between on‐treatment levels of total plasma apoB and Effect of more‐intensive cholesterol reducing regimens (ES 10/20, 2× statin, and R10) on the percent changes for various measures of Percent of individuals who reached (A) the 20th percentile target levels for At a glance, the drugs are equally effective. Free PMC article